Compare Uber Technologies Inc (UBER) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uber Technologies Inc vs Zoetis Inc — how do they compare? Uber Technologies Inc trades at $70.17 (market cap $139.81B), while Zoetis Inc trades at $73.02 (market cap $29.57B). The key difference: Uber Technologies Inc is far larger — about 4.7× Zoetis Inc's market cap, and Zoetis Inc pays a 2.96% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Uber Technologies Inc for 88 Days and Zoetis Inc for 70 Days on average.
| UBER | ZTS | |
|---|---|---|
Market Cap | $139.81B | $29.57B |
Volume | 11,879,194 | 4,128,093 |
Sector | Technology | Health |
52-Week High | $99.72 | $147.53 |
52-Week Low | $65.94 | $69.09 |
Typical Hold Time | 88 Days | 70 Days |
Enterprise Value | $149.15B | $37.13B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Uber (UBER) trades at $70.24, up 1.68% on the day, with a bearish technical signal from moving averages but strong fundamentals including 2025 revenue of $52.02 billion and net income of $10.05 billion. The company has beaten EPS estimates in two of the last three quarters and expanded its Uber Eats partnership with Costco to 47 states as of September 16, 2026. Operating cash flow grew to $10.10 billion in 2025, supporting a robust balance sheet with $6.98 billion in cash.
The outlook is positive given analyst consensus of a $104.72 price target and 82.54% buy ratings, though risks include a projected negative net cash flow in 2026 and competitive pressures from autonomous vehicle entrants. Upside is driven by earnings momentum and strategic expansions, while investor caution is warranted on execution and capital expenditure trends.
Zoetis (ZTS) trades at $73.08, up 2.47% on the day, but remains in a bearish technical trend with support near $70. Fundamentally, the company reported strong 2025 results with $9.47B revenue, $2.67B net income, and robust margins, though recent quarters show mixed earnings performance. Analyst consensus is a Buy with a $87.33 price target, but sentiment is cautious due to U.S. pet care weakness and competitive pressures.
The stock offers value with a P/E of 11.67 and a 3% dividend yield, but near-term headwinds include declining U.S. companion animal sales and margin compression. Long-term growth prospects remain intact given industry leadership and international resilience, making it a contrarian opportunity for patient investors despite technical and competitive risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
